Late-Breaking Data from the Phase 3 ASCENT-04/KEYNOTE-D19 Study Evaluating Trodelvy® plus Keytruda® in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer FOSTER CITY, Calif. & SANTA MONICA, Calif. — Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society of Clinical...
Latest News
FOSTER CITY, Calif. — Gilead Sciences, Inc., today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC...
– 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment FOSTER CITY, Calif. — Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study...
FOSTER CITY, Calif. — Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease. The two-year interim analysis includes people...
Gilteritinib may improve long-term outcomes, compared with salvage chemotherapy, in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), according to updated data from the ADMIRAL trial published in Blood. [1] The phase 3 ADMIRAL trial (ClinicalTrials.gov Identifier: NCT02997202) enrolled adults with FLT3-mutated AML who were in their first relapse after...
The family of a four-year-old girl with a rare genetic disorder are looking for auction and raffle prizes to help give something back to two charities that have helped her. Bethany Hepburn, of Washwood Close, Little Hulton, has Wolf Hirschhorn Syndrome, which severely restricts her development and has caused a...
Givinostat halted muscle shrinkage and fat infiltration in men with Becker muscular dystrophy (BMD) despite failing to ease muscle scarring, compared to a placebo, according to top-line, one-year results of an ongoing Phase 2 clinical trial. “We are very encouraged by the significant difference in muscle fat infiltration between the two groups after...
Primary and key secondary endpoints met, demonstrating a rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo · Cholestatic pruritus presents in the majority of PBC patients, with debilitating impacts on quality of life including sleep disturbance · Late-breaking results presented at the European Association for the...
SEATTLE – According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027). Key Trends and Analysis: The increasing incidence of myeloproliferative neoplasm is expected...
Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by absolute change from baseline at week 52, compared to placebo.1,2 Nerandomilast’s safety and tolerability profile was consistent across both trials, with similar rates...